NCT05077137View on ClinicalTrials.gov

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

PHASE1RecruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions

Melanoma

Interventions

BIOLOGICAL

Tetanus Diptheria Vaccine

tetanus and diphtheria toxoids

BIOLOGICAL

Polio Boost Immunization

trivalent inactivated polio vaccine

Trial Locations (1)

27710

RECRUITING

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER